We evaluated whether the dodecylamine derivative of hydroxocobalamin acts as a potent inhibitor of cobalamin-dependent enzymes in an African green monkey kidney cell, COS-7. When the dodecylamine derivative (1.0 μmol...We evaluated whether the dodecylamine derivative of hydroxocobalamin acts as a potent inhibitor of cobalamin-dependent enzymes in an African green monkey kidney cell, COS-7. When the dodecylamine derivative (1.0 μmol/L) did not show any cytotoxicity in the cultured cells, the derivative could not affect methylmalonyl-CoA mutase (holo-enzyme) activity, but significantly inhibit methionine synthase (holo-enzyme) activity in the cell homogenates of COS-7 grown in 1.0 μmol/L hydroxocobalamin-supplemented medium. An immunoblot analysis indicated that the dodecylamine derivative could not decrease the protein level of methionine synthase, but significantly inhibit the enzyme activity.展开更多
Aim To investigate the effects of JAK inhibitor （SHR0302） on adjuvant-induced arthritis （AA） rats and the partial mechanisms focused on T, B lymphocyte subsets through JAK1-STAT3 pathway, including Thl7, Treg, tot...Aim To investigate the effects of JAK inhibitor （SHR0302） on adjuvant-induced arthritis （AA） rats and the partial mechanisms focused on T, B lymphocyte subsets through JAK1-STAT3 pathway, including Thl7, Treg, total B cells and memory B cells. Methods Animals were divided randomly into 6 groups including normal control, AA, SHR0302 （0.3, 1.0, 3.0 nag · kg^-1, ig） and MTX （0.5 nag · kg^-1 , ig） . The effects of SHR0302 on AA rats by evaluating arthritis index, arthritis global assessment and paw swelling degree, histopathology of joint and spleen, inflammatory cytokine and antibody production in serum. We examined the proliferation of T, B and FLS by CCK8 kit; Thl7, Treg, total B and memory B cell proportion was measured by flow cytometry; Cytokines TNF-αβ, IL-1β, IL-10, IL-17 and antibody IgG1, IgG2a levels in serum were measured by ELISA kits; The ex- pression of p-JAK1 and p-STAT3 was measured by Western blot analysis. Results SHR0302 suppressed the se- verity of AA rats by attenuating the arthritis index, arthritis global assessment and paw swelling degree, and allevia- ted histopathology of spleen and joint of AA rats. SHR0302 can inhibit the proliferation of T, B and FLS, and down-regulated cytokines TNF-α, IL-1β, IL-17 and antibody IgG1, IgG2a levels, and suppressed the proportion of Thl7 and total B, and inhibited JAK1-STAT3 phosphorylation; There was no significant effect on Treg function and memory B cell proportion. Conclusion SHR0302 may attenuate the severity of AA rats, partially through signifi- cantly reducing Thl7 function and total B cell proportion by inhibiting JAK1-STAT3 phosphorylation.展开更多
BACKGROUND Remarkable progress over the last decade has equipped clinicians with many options in the treatment of inflammatory bowel disease.Clinicians now have the unique opportunity to provide individualized treatme...BACKGROUND Remarkable progress over the last decade has equipped clinicians with many options in the treatment of inflammatory bowel disease.Clinicians now have the unique opportunity to provide individualized treatment that can achieve and sustain remission in many patients.However,issues of primary non-response(PNR)and secondary loss of response(SLOR)to non-tumour necrosis factor inhibitor(TNFi)therapies remains a common problem.Specific issues include the choice of optimization of therapy,identifying when dose optimization will recapture response,establishing optimal dose for escalation and when to switch therapy.AIM To explores the issues of PNR and SLOR to non-TNFi therapies.METHODS This review explores the current evidence and literature to elucidate management options in cases of PNR/SLOR.It will also explore potential predictors for response following SLOR/PNR to therapies including the role of therapeutic drug monitoring(TDM).RESULTS In the setting of PNR and loss of response to alpha-beta7-integrin inhibitors and interleukin(IL)-12 and IL-23 inhibitors dose optimization is a reasonable option to capture response.For Janus kinase inhibitors dose optimization can be utilized to recapture response with loss of response.CONCLUSION The role of TDM in the setting of advanced non-TNFi therapies to identify patients who require dose optimization and as a predictor for clinical remission is not yet established and this remains an area that should be addressed in the future.展开更多
文摘We evaluated whether the dodecylamine derivative of hydroxocobalamin acts as a potent inhibitor of cobalamin-dependent enzymes in an African green monkey kidney cell, COS-7. When the dodecylamine derivative (1.0 μmol/L) did not show any cytotoxicity in the cultured cells, the derivative could not affect methylmalonyl-CoA mutase (holo-enzyme) activity, but significantly inhibit methionine synthase (holo-enzyme) activity in the cell homogenates of COS-7 grown in 1.0 μmol/L hydroxocobalamin-supplemented medium. An immunoblot analysis indicated that the dodecylamine derivative could not decrease the protein level of methionine synthase, but significantly inhibit the enzyme activity.
文摘Aim To investigate the effects of JAK inhibitor （SHR0302） on adjuvant-induced arthritis （AA） rats and the partial mechanisms focused on T, B lymphocyte subsets through JAK1-STAT3 pathway, including Thl7, Treg, total B cells and memory B cells. Methods Animals were divided randomly into 6 groups including normal control, AA, SHR0302 （0.3, 1.0, 3.0 nag · kg^-1, ig） and MTX （0.5 nag · kg^-1 , ig） . The effects of SHR0302 on AA rats by evaluating arthritis index, arthritis global assessment and paw swelling degree, histopathology of joint and spleen, inflammatory cytokine and antibody production in serum. We examined the proliferation of T, B and FLS by CCK8 kit; Thl7, Treg, total B and memory B cell proportion was measured by flow cytometry; Cytokines TNF-αβ, IL-1β, IL-10, IL-17 and antibody IgG1, IgG2a levels in serum were measured by ELISA kits; The ex- pression of p-JAK1 and p-STAT3 was measured by Western blot analysis. Results SHR0302 suppressed the se- verity of AA rats by attenuating the arthritis index, arthritis global assessment and paw swelling degree, and allevia- ted histopathology of spleen and joint of AA rats. SHR0302 can inhibit the proliferation of T, B and FLS, and down-regulated cytokines TNF-α, IL-1β, IL-17 and antibody IgG1, IgG2a levels, and suppressed the proportion of Thl7 and total B, and inhibited JAK1-STAT3 phosphorylation; There was no significant effect on Treg function and memory B cell proportion. Conclusion SHR0302 may attenuate the severity of AA rats, partially through signifi- cantly reducing Thl7 function and total B cell proportion by inhibiting JAK1-STAT3 phosphorylation.
文摘BACKGROUND Remarkable progress over the last decade has equipped clinicians with many options in the treatment of inflammatory bowel disease.Clinicians now have the unique opportunity to provide individualized treatment that can achieve and sustain remission in many patients.However,issues of primary non-response(PNR)and secondary loss of response(SLOR)to non-tumour necrosis factor inhibitor(TNFi)therapies remains a common problem.Specific issues include the choice of optimization of therapy,identifying when dose optimization will recapture response,establishing optimal dose for escalation and when to switch therapy.AIM To explores the issues of PNR and SLOR to non-TNFi therapies.METHODS This review explores the current evidence and literature to elucidate management options in cases of PNR/SLOR.It will also explore potential predictors for response following SLOR/PNR to therapies including the role of therapeutic drug monitoring(TDM).RESULTS In the setting of PNR and loss of response to alpha-beta7-integrin inhibitors and interleukin(IL)-12 and IL-23 inhibitors dose optimization is a reasonable option to capture response.For Janus kinase inhibitors dose optimization can be utilized to recapture response with loss of response.CONCLUSION The role of TDM in the setting of advanced non-TNFi therapies to identify patients who require dose optimization and as a predictor for clinical remission is not yet established and this remains an area that should be addressed in the future.
